Tango Therapeutics, Inc. 8-K

What Happened

• On June 9, 2026, Tango Therapeutics (TNGX) entered an underwriting agreement with J.P. Morgan Securities LLC and Leerink Partners LLC for an underwritten public offering. The offering consists of 18,166,667 common shares and pre-funded warrants to purchase up to 1,833,395 common shares. Each share was offered at $30.00 and each pre-funded warrant at $29.999 (reflecting a $0.001 exercise price).
• The underwriters have a 30-day option to buy up to an additional 3,000,009 shares. The offering is expected to close on June 11, 2026, subject to customary closing conditions. Tango estimates net proceeds of approximately $566.5 million after underwriting discounts and estimated offering expenses. The company intends to use proceeds for general corporate purposes, including research and development, expenses for its pivotal trial(s) and commercialization preparation, G&A and capital expenditures.

Key Details

• Offering: 18,166,667 firm shares + pre-funded warrants for up to 1,833,395 shares; $30.00 per share; pre-funded warrant price $29.999.
• Option: Underwriters may purchase up to 3,000,009 additional shares within 30 days.
• Net proceeds: ~ $566.5 million expected to the company after fees and expenses.
• Runway: Company states proceeds plus existing cash should fund operations and capital needs into 2030.

Why It Matters

• This financing materially increases Tango’s liquidity, providing capital to advance R&D, support a pivotal trial and prepare for potential product commercialization without immediate reliance on other financing.
• The use of pre-funded warrants allows investors who want to avoid immediate dilution (or exceed ownership limits tied to common shares) to participate; however, exercise mechanics include ownership caps (default 4.99% or 9.99%, adjustable up to 19.99% with notice), which can affect who can convert warrants.
• The potential additional 3.0M-share option (overallotment) could increase dilution if exercised. Investors should weigh the funding and runway benefits against dilution from the new shares and warrants.